A Bayesian dose finding design for oncology clinical trials of combinational biological agents

Journal of the Royal Statistical Society. Series C: Applied Statistics

Volumn 63, Issue 1, 2014, Pages 159-173

  Cai, Chunyan ^a   Yuan, Ying ^b   Ji, Yuan ^c  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

Author keywords

Adaptive design; Biologically optimal dose combination; Change point model; Dose finding; Drug combination; Non monotonic pattern

Indexed keywords

EID: 84890874592     PISSN: 00359254     EISSN: 14679876     Source Type: Journal    
DOI: 10.1111/rssc.12039     Document Type: Article

References (20)

1. Braun, T. M. and Wang, S. (2010) A hierarchical Bayesian design for phase I trials of novel combinations of cancer therapeutic agents. Biometrics, 66, 805-812.
2. Conaway, M. R., Dunbar, S. and Peddada, S. D. (2004) Designs for single- or multiple-agent phase i trials. Biometrics, 60, 661-669.
3. Gelman, A., Jakulin, A., Pittau, M. G. and Su, Y.-S. (2008) A weakly informative default prior distribution for logistic and other regression models. Ann. Appl. Statist., 2, 1360-1383.
4. Hoff, P. M. and Ellis, L. M. (2007) Targeted therapy trials: approval strategies, target validation, or helping patients? J. Clin. Oncol., 25, 1639-1641.
5. Huang, X., Biswas, S., Oki, Y., Issa, J.-P. and Berry, D. A. (2007) A parallel phase I/II clinical trial design for combination therapies. Biometrics, 63, 429-436.
6. Ihle, N. T. and Powis, G. (2009) Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy. Molec. Cancer Therpeutcs, 8, 1-9.
7. Kramar, A., Lebecq, A. and Candalh, E. (1999) Continual reassessment methods in phase I trials of the combination of two drugs in oncology. Statist. Med., 18, 1849-1864.
8. Mandrekar, S. J., Cui, Y. and Sargent, D. J. (2007) An adaptive phase I design for identifying a biologically optimal dose for dual agent drug combinations. Statist. Med., 26, 2317-2330.
9. Mandrekar, S. J. and Sargent, D. J. (2009) Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges. J. Clin. Oncol., 27, 4027-4034.
10. Murtaugh, P. A. and Fisher, L. D. (1990) Bivariate binary models of efficacy and toxicity in dose-ranging trials. Communs Statist. Theor. Meth., 19, 2003-2020.
11. O'Quigley, J., Pepe, M. and Fisher, L. (1990) Continual reassessment method: a practical design for phase 1 clinical trials in cancer. Biometrics, 46, 33-48.
12. Paoletti, X. and Kramar, A. (2009) A comparison of model choices for the continual reassessment method in phase I cancer trials. Statist. Med., 28, 3012-3028.
13. Smith, S. M., Besien, K., Karrison, T., Dancey, J., Mclaughlin, P., Younes, A., Smith, S., Stiff, P., Lester, E., Modi, S., Doyle, L. A., Vokes, E. E. and Pro, B. (2010) Temsirolimus has activity in nonmantle cell non-Hodgkins lymphoma subtypes: The University of Chicago phase II consortium. J. Clin. Oncol., 28, 4740-4746.
14. Thall, P. F. and Cook, J. D. (2004) Dose-finding based on efficacy-toxicity trade-offs. Biometrics, 60, 684-693.
15. Thall, P. F., Millikan, R. E., Mueller, P. and Lee, S.-J. (2003) Dose-finding with two agents in phase I oncology trials. Biometrics, 59, 487-496.
16. Wages, N. A., Conaway, M. R. and O'Quigley, J. (2011) Continual reassessment method for partial ordering. Biometrics, 67, 1555-1563.
17. Wang, K. and Ivanova, A. (2005) Two-dimensional dose finding in discrete dose space. Biometrics, 61, 217-222.
18. Yin, G. and Yuan, Y. (2009) Bayesian dose finding in oncology for drug combinations by copula regression. Appl. Statist., 58, 211-224.
19. Yuan, Y. and Yin, G. (2008) Sequential continual reassessment method for two-dimensional dose finding. Statist. Med., 27, 5664-5678.
20. Yuan, Y. and Yin, G. (2011) Robust EM continual reassessment method in oncology dose finding. J. Am. Statist. Ass., 106, 818-831.